Moderna and Merck report promising results from cancer vaccine amid early skepticism

Moderna and Merck say their experimental mRNA cancer vaccine has produced encouraging mid‑stage data, shifting the narrative from doubt to optimism.

At a March 2023 leadership meeting, executives were asked to stand if they expected the vaccine to succeed; only the company president did, underscoring the widespread skepticism within the firms.

The latest readout, released last Wednesday, convinced many observers that the approach can work despite the logistical hurdles and pandemic‑era complications that have plagued the program.

The positive outcome highlights the growing potential of mRNA technology in oncology and may shape future investment and development strategies in the sector.